Fosun Pharma USA Inc.

Jeremy L. T. is heading to DCAT (Drug, Chemical & Associated Technologies Association) Week 2025 in NYC! As the premier event for pharmaceutical development and manufacturing professionals, it’s the perfect opportunity to connect, collaborate, and drive innovation forward. Are you attending? Jeremy is ready to discuss partnerships, and innovative strategies, and explore how we can create real impact together. ?? March 17-20 ?| ?New York City ?? Meeting times are limited—schedule a meeting today! Send us a DM to lock in a time. Let’s make things happen at #DCATWeek2025!

Christine Devlin and Greg Stofko, MBA had a fantastic time at the ECRM Generic Rx Session, where they reaffirmed their commitment to quality, reliability, and strong partnerships in the industry. Connecting with over 100 customers—both new and long-standing—was a highlight, and the energy around future opportunities was undeniable. As they take this next week to follow up, they’re already seeing promising new relationships and exciting business growth on the horizon. A huge thank you to everyone they met—they’re looking forward to what’s next! #ecrm

We’re excited to attend the IASLC 2025 Targeted Therapies of Lung Cancer (TTLC) Meeting at the Hyatt Regency Resort and Spa from February 19-22, 2025, in Huntington Beach, CA. Visit us! Our team will be at BOOTH 18. Join us to connect, explore cutting-edge research, and be part of a new era in targeted lung cancer therapies! ? To stay connected on new insights, visit our website to sign-up for updates https://lnkd.in/ekcwZZmT #TTLC2025 #FosunPharmaUSA #IASLC2025 ???????????????????????????????????????????????????????????????????????????????????????

Happy 2025 Chinese New Year! Wishing everyone prosperity, wisdom, and transformation as we celebrate the Year of the Snake. May this year bring you success, resilience, and new opportunities to grow. #InnovativeMedicines #FosunPharmaUSA #HealthcareInnovation #OncologyLeadership #ES-SCLC

We are Fosun Pharma USA—and we’re moving faster than ever to reshape the future of cancer care. We're working tirelessly for our patients by taking on the most challenging solid tumors: Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Gastric Cancer. With 3 ground-breaking treatments in development working towards?US approval: -??Serplulimab Our innovative anti-PD-1 monoclonal antibody therapy, Serplulimab, reached significant clinical milestones. We successfully accelerated the ASTRIDE trial (NCT05468489) in the U.S. - ?Foritinib (SAF-189s) A Promising Innovation in Lung Cancer Treatment, SAF-189, a highly potent and brain-penetrating next-generation ALK/ROS1 inhibitor candidate, demonstrated compelling results in clinical trials. - HLX22 Fosun Pharma’s novel HER2-targeting antibody, HLX22, entered a Global Phase 3 clinical trial. We expect the first U.S. sites to be opened in early 2025. We’re addressing unmet needs—showing that rapid growth and innovation go hand in hand, with no patient left behind. With respective opportunities associated and held by our affiliates—134 preclinical treatments and 76 clinical-stage innovations,?we're proving that providing innovation for good health is more than a mission—it’s a passion that drives us to grow faster and?reach farther to serve patients who need us the most. Join us! Together, we can change the future of cancer care. #InnovativeMedicines #FosunPharmaUSA #HealthcareInnovation #OncologyLeadership #ES-SCLC? Meet us at the JP Morgan Healthcare Conference #JPM2025 To schedule a meeting, click this link: https://lnkd.in/gK-qhv-s

We are Fosun Pharma USA—and we’re moving faster than ever to reshape the future of cancer care. We're working tirelessly for our patients by taking on the most challenging solid tumors: - Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Gastric Cancer. With 3 ground-breaking treatments in development working towards?US approval: - Serplulimab Our innovative anti-PD-1 monoclonal antibody therapy, Serplulimab, reached significant clinical milestones. We successfully accelerated the ASTRIDE trial (NCT05468489) in the U.S. - Foritinib (SAF-189s) A Promising Innovation in Lung Cancer Treatment, SAF-189, a highly potent and brain-penetrating next-generation ALK/ROS1 inhibitor candidate, demonstrated compelling results in clinical trials. - HLX22 Fosun Pharma’s novel HER2-targeting antibody, HLX22, entered a Global Phase 3 clinical trial. We expect the first U.S. sites to be opened in early 2025. We’re addressing unmet needs—showing that rapid growth and innovation go hand in hand, with no patient left behind. With respective opportunities associated and held by our affiliates—134 preclinical treatments and 76 clinical-stage innovations,?we're proving that providing innovation for good health is more than a mission—it’s a passion that drives us to grow faster and?reach farther to serve patients who need us the most. Join us! Together, we can change the future of cancer care. #FosunPharmaUSA #HealthcareInnovation #OncologyLeadership #ES-SCLC Meet us at the JP Morgan Healthcare Conference #jpm2025 To schedule a meeting at JPM, click this link: https://lnkd.in/gK-qhv-s ?

We’re excited to join the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, at the San Francisco Marriott Marquis. Let’s Meet! Our team will be at the San Francisco Marriott Marquis, located at 780 Mission St. We look forward to exploring new opportunities and collaborations as we work together to change the future of cancer care. To schedule a meeting, click this link: https://lnkd.in/gK-qhv-s #JPMC2025 #FosunPharmaUSA #HealthcareInnovation

We’re excited to join the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, at the San Francisco Marriott Marquis. Let’s Meet! Our team will be at the San Francisco Marriott Marquis, located at 780 Mission St. We look forward to exploring new opportunities and collaborations as we work together to change the future of cancer care. To schedule a meeting, click this link: https://lnkd.in/gK-qhv-s #JPMC2025 #FosunPharmaUSA #HealthcareInnovation

We’re excited to join the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, at the San Francisco Marriott Marquis Let’s Meet! Our team will be at the San Francisco Marriott Marquis, located at 780 Mission St. We look forward to exploring new opportunities and collaborations as we work together to change the future of cancer care. To schedule a meeting follow this link: https://lnkd.in/gK-qhv-s #JPMC2025 #FosunPharmaUSA #HealthcareInnovation